ANTI CANCER

ALA’s cell targeting cancer treatment works in mice - human trials on track with manufacturing scale now achieved

Next Investors Jun 07, 2024

Our biotech Investment, Arovella Therapeutics (ASX: ALA) is developing an iNKT cell therapy platform to fight cancer, and is setting the stage for a Phase 1 clinical trial. Basically ALA’s treatment can find, identify and kill specific cancer cells, leaving other healthy cells unharmed,

ALA now funded to enter Phase 1 trial to test new cancer treatment tech on humans…

Next Investors Mar 26, 2024

Our Investment ALA is trialling a technology to find, target and attack ONLY cancer cells, leaving the rest of the body healthy and unimpacted.

ALA on the Pathway to Phase I Clinical Trials

Next Investors Apr 21, 2022

Our biotech investment, Arovella Therapeutics (ASX:ALA), is one of only a handful of companies in the world working on an iNKT cell therapy for cancer.

OncoSil granted FDA Breakthrough Device Designation

Finfeed Archived Mar 18, 2020

OncoSil Medical Ltd’s (ASX: OSL) OncoSil™ device has reached a significant milestone, receiving Breakthrough Device Designation by the US FDA for the treatment of unresectable locally advanced pancreatic cancer.

ASX MedTech Junior Displays Promise for Pancreatic Cancer Patients

Next Investors Archived Jan 30, 2020

OncoSil Medical (ASX: OSL) has developed a first-in-class, truly innovative device that treats unresectable locally advanced pancreatic cancer — that is, tumours that can’t be surgically removed.

Childhood cancer research gets million dollar boost

Finfeed Archived Dec 16, 2019

Australian Lions Childhood Cancer Research Foundation has announced it will provide $1.05 million of funding to the Telethon Kids Institute.

Prescient trials show total eradication of cancer

Finfeed Archived Nov 28, 2019

Shares in Prescient Therapeutics Limited (ASX:PTX) surged 50% on Wednesday after the clinical stage oncology company developing personalised medicine approaches to cancer released promising news.

Interview: Mike Harsh on the evolution of Imaging and Imagion's role

Finfeed Archived Nov 18, 2019

With over 40 years’ experience in the healthcare diagnostic imaging industry, Imagion Biosystems (ASX:IBX) Board member Mike Harsh is one of the world’s most qualified people to speak about the evolution of diagnostics.

Imagion cancer detection technology receives approval in India

Finfeed Archived Nov 13, 2019

Imagion Biosystems Limited (ASX:IBX) has been issued patent #320872 from the Government of India Patent Office.

ASX Junior Has Early Success With K9 Cancer Trials: Human Trials Await

Next Investors Archived Nov 07, 2019

One ASX listed clinical stage oncology company is developing novel targeted cancer therapeutics for both humans and animals.

PharmAust has success with gelatin encapsulated liquid monepantel

Finfeed Archived Nov 04, 2019

Clinical stage oncology company, PharmAust Ltd (ASX:PAA) has provided recruitment guidance for its anti-cancer trialling goals with treatment naïve B cell lymphoma.

PharmAust set to restart cancer drug trials in pets

Finfeed Archived Nov 01, 2019

Clinical-stage oncology company, PharmAust (ASX:PAA) has released its quarterly, highlighting the company's recent successes.

IMU Poised to Break into Oncolytic Virotherapy Space with Novel Cancer Therapy

Next Investors Archived Oct 24, 2019

The proposal for the exclusive license of patents covering the CF33 OV technology will be put to Imugene (ASX:IMU) shareholders for their approval at an Extraordinary Meeting of Shareholders to be held on 18 November.

City of Hope receives US DoD grant with upside for Imugene

Finfeed Archived Oct 23, 2019

A US Department of Defense Grant has been awarded to renowned City of Hope researchers to fund research into gastric cancer, a disease that disproportionately affects US military service members, veterans, and their beneficiaries.

Imugene to demonstrate the benefits of combination tumor treatment

Finfeed Archived Oct 21, 2019

Imugene Limited (ASX:IMU) has provided a promising update on the preliminary clinical development plan (CDP) for the proposed exclusive license of the patents covering the CF33 oncolytic virus technology.

GTG Signs Prestigious Collaboration Agreement for Fight Against Cancer

Next Investors Archived Oct 02, 2019

Emerging med-tech junior Genetic Technologies (ASX:GTG | NASDAQ:GENE) understands the importance of timely and precise targeting. Accessible predictive risk testing is where GTG lives and it has now signed a 3-year Collaboration Agreement with high profile US-based researcher Translational Genomics Research Institute (TGen).

Genetic Technologies surges 40% on back of agreement

Finfeed Archived Sep 23, 2019

Provider of world-leading genetic risk assessment test products Genetic Technologies Limited (ASX:GTG), has signed a 3-year Collaboration Agreement with TGen.

Rhythm’s lead biomarker successfully differentiates between cancer and healthy samples

Finfeed Archived Sep 19, 2019

New antibodies for the key lead biomarker used in Rhythm Biosciences' (ASX: RHY) ColoSTAT® test can successfully differentiate between cancer and healthy samples, and the test has now been optimised.

Anti Cancer